GregoryPKalemkerianMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Kalemkerian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kalemkerian's full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1989 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1985 - 1989
Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

MI State Medical License 1993 - 2027
MD State Medical License 1989 - 1994
IL State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC Start of enrollment: 2002 Mar 01
Completed
Phase 2
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Start of enrollment: 2007 Sep 01
Completed
Phase 2
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Start of enrollment: 2016 Mar 15
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 05
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

53 citations
High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.
Mina Zeinali, Maggie Lee, Arthi Nadhan, Anvya Mathur, Casey Hedman
Cancers. 2020-01-03
105 citations
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares
Nature Medicine. 2022-08-01
381 citations
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 ...
Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters
Journal of Clinical Oncology. 2020-05-29

Journal Articles

The EGFR T790M Mutation Is Acquired Through AICDA-Mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer
Gregory P Kalemkerian, Khaled A Hassan, Clinical Cancer Research

Other

Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer
Kalemkerian GP, Baldini EH
http://www.uptodate.com/contents/chemoradiotherapy-for-the-initial-treatment-of-limited-stage-small-
UpToDate, Wolters Kluwer Health - 2013-03-18